<DOC>
	<DOCNO>NCT02420509</DOCNO>
	<brief_summary>The purpose study find postoperative chemotherapy patient high-grade appendix cancer surgery improve outcomes . The postoperative chemotherapy consist 5-FU ( leucovorin ) capecitabine bevacizumab . These drug approve use people colon cancer , use UCSD patient appendix cancer . The purpose study explore safety efficacy postoperative chemotherapy treatment cancer .</brief_summary>
	<brief_title>Postoperative Chemotherapy High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis</brief_title>
	<detailed_description>This observational , single-cohort , prospective study systemic chemotherapy CRS/HIPEC . Subjects give twelve month 5-FU capecitabine bevacizumab start 4-16 week surgery . CTRI Biostatistics Core personnel assist conduct analysis use late version R ( R Foundation Statistical Computing , Vienna , Austria . http : //www.R-project.org/ ) . No therapy include study . Subjects already previously undergone surgery cancer . This study observe outcomes postoperative chemotherapy treatment doctor choose treat subject 's cancer .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>3.1 Inclusion Criteria Patients must meet inclusion criterion participate study . 1 . Ability understand willingness sign write informed consent . 2 . Highgrade peritoneal carcinomatosis appendiceal adenocarcinoma . 1 . Moderate poorlydifferentiated adenocarcinoma , signet ring cell carcinoma `` highgrade '' carcinoma ( primary tumor extraappendiceal metastasis ) designate standardized pathologic testing.23,24 2 . May initially determine preCRS/HIPEC tumor pathology ( screen purpose ) , must confirm pathology resect tumor part CRS/HIPEC . 3 . Have complete ( CC0 CC1 ) CRS HIPEC open minimally invasive ( laparoscopic robotic ) 4 . Have receive plan receive 12 month postoperative chemotherapy , start sooner 4 week longer 16 week CRS/HIPEC , consist : 1 . 5fluorouracil ( Adrucil® ) 400 mg/m2 IV bolus 2400 mg/m2 IV continuous infusion x 46hrs , leucovorin ( Leucovorin Calcium ) 20 mg/m2 IV bolus bevacizumab ( Avastin® ) 5 mg/kg IV every two week total 12 month ( 26 cycle ) ; OR 2 . Capecitabine ( Xeloda® ) 1250 mg/m2 PO twice daily 14 day , 7day break , bevacizumab ( Avastin® ) 7.5 mg/kg IV every three week , total 12 month ( 17 cycle ) . 5 . Have receive plan receive standard clinical , biochemical radiographic surveillance , consist : 1 . Adverse event assessment every chemotherapy cycle end treatment 2 . CEA , CA199 CA 125 ) Every 1 month x 1 year ( treatment ) , ii ) Every 1 month x 6 month , iii ) Every 3 month x 1.5 year , iv ) Every 6 month x 1 year c ) CT chest , abdomen pelvis MRI ) Every 3 month x 1 year ( treatment ) , ii ) Every 3 month x 1 year , iii ) Every 6 month x 1 year , iv ) Every 12 month x 1 year 6 . Age &gt; 18 year old 7 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 ( Appendix A ) . 8 . Adequate organ bone marrow function define : 1 . Absolute Neutrophil Count ≥ 1.5 x 109/L 2 . Platelet count ≥ 100 x 109/L 3 . Hemoglobin ≥ 9.0 g/dL 4 . Total bilirubin ≤ 1.5 x ULN 5 . AST/SGOT ALT/SPGT ≤ 2.5 X ULN 6 . Serum creatinine ≤ 1.5 x ULN 9 . Women childbearing potential men partner childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 90 day follow completion therapy . ) A woman childbearing potential female ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) meet follow criterion : ) Has undergone hysterectomy bilateral oophorectomy ; ii ) Has naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) 10 . Women childbearing potential must negative pregnancy test prior initiate study drug treatment . 3.2 Exclusion Criteria Subjects meeting exclusion criterion baseline exclude study participation . 1 . Current anticipate use investigational agent . 2 . Patients receive systemic chemotherapy radiotherapy within two month prior first schedule cycle postoperative chemotherapy . 3 . Patients less 4 week CRS/HIPEC insufficient recovery surgicalrelated trauma wound healing determine patient 's surgeon . 4 . History hypersensitivity reaction specifically attribute compound similar chemical biologic composition 5FU , leucovorin , capecitabine bevacizumab . 5 . History deep venous thrombosis ( DVT ) pulmonary embolism ( PE ) . 6 . Concurrent active measurable malignancy , except basal cell carcinoma squamous cell carcinoma skin . 7 . Severe uncontrolled medical disorder would , investigator 's opinion , impair ability receive study treatment ( i.e. , uncontrolled diabetes , chronic renal disease , chronic pulmonary disease active , uncontrolled infection , psychiatric illness/social situation would limit compliance study requirement ) . 8 . Known diagnosis human immunodeficiency virus ( HIV ) infection . 9 . Incarcerated patient . 10 . Pregnant nursing woman , due potential congenital abnormality regimen harm nursing infant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>